Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.
复制标题
类风湿关节炎患者的抗核抗体和抗双链DNA抗体与英夫利昔单抗的临床反应的相关性：一项回顾性临床研究。
DOI：
10.1186/ar3546
复制
发表时间：
2011
影响因子：
4.9
通讯作者：
Mimori T
中科院分区：
文献类型：
--
作者：
Yukawa N;Fujii T;Kondo-Ishikawa S;Yoshifuji H;Kawabata D;Nojima T;Ohmura K;Usui T;Mimori T
类风湿关节炎(RA)经英夫利昔单抗(IFX)治疗后产生抗核抗体(ANA)或抗双链DNA抗体(DS-DNA)是众所周知的现象，但这些抗体与IFX临床疗效的相关性尚未确定。这项回顾性观察研究的目的是检测类风湿关节炎患者在IFX治疗前后ANA和抗ds-DNA抗体阳性的发生率，并调查此类抗体滴度的增加是否与IFX的临床疗效有关。对111例接受IFX治疗的类风湿关节炎患者进行研究。检测IFX治疗前后Hep-2细胞间接免疫荧光法(ANA)和抗ds-DNA抗体(Farr法)检测结果。根据EULAR反应标准评定的总体临床反应如下：良好反应占55%，其中缓解占38%；中等反应占18%；无反应(NOR)占27%。抗核抗体(≥1：16 0)和抗ds-DNA抗体的阳性率分别从25%上升到40%(P=0.0 3)和从3%上升到26%(P<；0.001)。IFX前ANA滴度与EULAR疗效差异有统计学意义(P=0.001)，IFX治疗效果随IFX前ANA滴度增加而变差。此外，在IFX≤1：80和≥1：160之前，抗核抗体滴度的临床反应差异有统计学意义(≤1：80组好、中和无反应分别为66%、9%和25%；≥1：160组分别为26%、33%和41%；P<；0.001)。IFX后ANA升高的13例患者中，10例表现为NOR，仅1例反应良好，无一例缓解。这些临床反应与ANA无变化的患者有显著差异。IFX后抗ds-DNA抗体阳性21例，NOR 16例，仅2例反应良好，无一例缓解。目前的研究表明，开始使用IFX前的ANA滴度可以预测对IFX的临床反应。IFX后ANA或抗ds-DNA抗体滴度升高可能是NOR的有用标志物。
The induction of antinuclear antibodies (ANAs) or anti-double-stranded (ds) -DNA antibodies (Abs) after infliximab (IFX) therapy in rheumatoid arthritis (RA) is a well-known phenomenon, but the correlation of such Abs with the clinical response to IFX has not yet been determined. The aims of this retrospective observational study were to examine the prevalence of positive ANA and anti-ds-DNA Abs before and after IFX therapy in patients with RA and to investigate whether an increased titer of such Abs is associated with the clinical efficacy of IFX. One hundred eleven RA patients who had received IFX were studied. ANA (indirect immunofluorescence with HEp-2 cells) and anti-ds-DNA Abs (Farr assay) results were examined before and after IFX therapy. The overall clinical response assessed by EULAR response criteria was as follows: good response in 55%, including remission in 38%; moderate response in 18%; and no response (NOR) in 27%. The positivity of ANA (≥ 1:160) and anti-ds-DNA Abs significantly increased from 25% to 40% (P = 0.03) and from 3% to 26% (P < 0.001) after IFX, respectively. EULAR response differed significantly according to the ANA titer before IFX (P = 0.001), and the efficacy of IFX became worse as the ANA titer before starting IFX increased. Furthermore, the differences in the clinical response of the ANA titer before IFX ≤ 1:80 and ≥ 1:160 were significant (good, moderate, and no response were 66%, 9%, and 25% in ≤ 1:80 group versus 26%, 33%, 41% in ≥ 1:160 group, respectively; P < 0.001). In 13 patients whose ANA had increased after IFX, 10 showed NOR, only one showed a good response, and none reached remission. These clinical responses were significantly different from ANA no-change patients. In 21 patients with positive anti-ds-DNA Abs after IFX, 16 showed NOR, only two showed a good response, and none reached remission. The present study suggests that the ANA titer before starting IFX predicts the clinical response to IFX. The increased titers of ANA or anti-ds-DNA Abs after IFX may be useful markers of NOR.
登录
查看更多内容
影响因子：
--
作者：
Goekoop-Ruiterman, YPM;de Vries-Bouwstra, JK;Dijkmans, C
通讯作者：
Dijkmans, C
影响因子：
4.9
作者：
Kapetanovic, Meliha C.;Larsson, Lotta;Geborek, Pierre
通讯作者：
Geborek, Pierre
影响因子：
--
作者：
Mitoma, Hiroki;Horiuchi, Takahiko;Harada, Mine
通讯作者：
Harada, Mine
影响因子：
--
作者：
De Rycke, L;Baeten, D;De Keyser, F
通讯作者：
De Keyser, F
影响因子：
64.8
作者：
JACOB, CO;MCDEVITT, HO
通讯作者：
MCDEVITT, HO